

# Antimicrobial Susceptibility Test Results for Gram-negative isolates recovered from adult and paediatric clinical specimens: 2020

Department of Clinical Microbiology, Auckland City Hospital. Clinical Microbiologists can be contacted through Lablink on 09 3078995 or 0800 5227587



≥ 90% susceptible;
  70-89% susceptible;
  < 70% susceptible;
 Number = proportion susceptible (S/I)    R = Resistant

Classification Number: LPMICCOMIN008 Date of issue: July 2021	Amoxicillin	Amoxicillin-clavulanate	Cephalexin <sup>d</sup>	Cefuroxime	Ceftriaxone	Ceftazidime	Piperacillin-tazobactam	Aztreonam	Meropenem	Gentamicin	Amikacin	Trimethoprim <sup>d</sup>	Cotrimoxazole	Ciprofloxacin	Norfloxacin <sup>c,d</sup>	Nitrofurantoin <sup>d</sup>
Organism (number tested)																
<i>Escherichia coli</i> – all (3611) <sup>a</sup>	39	75	75	83	89	-	92	89	100	89	100	66	68	80	77	99
ESBL <i>Escherichia coli</i> (308)	R	R	R	R	R	R	-	R	100	50	99	31	33	20	16	97
<i>Klebsiella pneumoniae</i> – all (690)	R	85	85	84	90	-	86	90	100	92	100	76	80	84	80	73
ESBL <i>Klebsiella pneumoniae</i> (98)	R	R	R	R	R	R	-	R	100	55	98	34	37	41	37	63
<i>Klebsiella oxytoca</i> (165)	R	80	78	78	84	-	82	84	100	94	100	86	88	92	92	98
<i>Klebsiella (Enterobacter) aerogenes</i> (97)	R	R	R	R	77 <sup>b</sup>	-	75	78	100	99	100	97	98	98	97	84
<i>Proteus mirabilis</i> (289)	72	89	94	97	99	-	98	99	100	91	100	75	78	92	94	R
<i>Proteus vulgaris</i> (21)	R	76	R	R	95 <sup>b</sup>	-	100	100	100	100	100	81	81	100	100	R
<i>Enterobacter cloacae</i> complex (236)	R	R	R	R	70 <sup>b</sup>	-	66	73	100	96	100	87	91	95	92	93
<i>Serratia marcescens</i> (197)	R	R	R	R	98 <sup>b</sup>	-	97	99	100	99	99	97	99	95	94	R
<i>Morganella morganii</i> (93)	R	R	R	R	97 <sup>b</sup>	-	93	97	100	84	100	83	83	77	77	R
<i>Citrobacter koseri</i> (107)	R	97	97	91	97	-	99	97	100	96	100	100	100	98	97	98
<i>Citrobacter freundii</i> (27)	R	R	R	R	59 <sup>b</sup>	-	64	70	100	96	100	85	85	100	100	100
<i>Pseudomonas aeruginosa</i> (774)	R	R	R	R	R	90	93	92	96	See note <sup>f</sup>	96	R	R	88	-	R
<i>Stenotrophomonas maltophilia</i> (65)	R	R	R	R	R	-	R	R	R	R	R	-	98	-	-	-
<i>Acinetobacter</i> spp. (49)	R	R	R	R	-	94	94	-	100	96	100	-	100	92	-	-
<i>Haemophilus influenzae</i> (246) <sup>e</sup>	57	71	-	-	96	-	99	-	-	-	-	-	72	-	-	-

<sup>a</sup> 95% and 92% ESBL *E. coli* susceptible to fosfomycin and mecillinam respectively

<sup>b</sup> *E. cloacae*, *K. aerogenes*, *S. marcescens*, *M. morganii*, *C. freundii* and *P. vulgaris* may develop resistance during prolonged treatment with third generation cephalosporins

<sup>c</sup> Norfloxacin should be reserved for infections caused by resistant urinary isolates

<sup>d</sup> Cephalexin, nitrofurantoin, trimethoprim, and norfloxacin results apply to lower urinary tract infection only

<sup>e</sup> 98% of *H. influenzae* isolates were susceptible to tetracycline/doxycycline.

<sup>f</sup> 91% of *P. aeruginosa* have wild-type in-vitro susceptibility to gentamicin

See [http://www.surv.esr.cri.nz/antimicrobial/neisseria\\_meningitidis.php](http://www.surv.esr.cri.nz/antimicrobial/neisseria_meningitidis.php) for information on antimicrobial susceptibility among *Neisseria meningitidis* isolates.